On Monday, the U.S. Food and Drug Administration (FDA) extended the review date for Sanofi SA’s (NASDAQ:SNY) new drug application (NDA) of tolebrutinib for non-relapsing, secondary progressive ...

Updates in relapsing-remitting MS from ECTRIMS 2025 examine lifestyle interventions, anti-CD20 therapies, efficacy of fenebrutinib, and bone marrow transplantation as an effective long-term treatment.

Update on the US regulatory review of tolebrutinib in non-relapsing, secondary progressive multiple sclerosis Paris, September 22, 2025. The US Food and Drug Administration (FDA) has extended by three ...

Additional early research suggested that combining metformin and clemastine may promote remyelination, offering hope for ...

Paris, September 22, 2025. The US Food and Drug Administration (FDA) has extended by three months the target action date of its review of the new drug application (NDA) of tolebrutinib, an oral and ...